logo

Moleculin Biotech Inc (MBRX)



Trade MBRX now with
  Date
  Headline
7/10/2019 7:31:32 AM Moleculin Files For New Patents For Annamycin After Receiving FDA Approval Of Fast Track Designation
5/14/2019 7:33:22 AM Moleculin Biotech Q1 Loss Per Share $0.14 Vs Loss $0.08 Last Year
4/23/2019 8:42:21 AM Moleculin Biotech Announces $15.0 Mln Registered Direct Offering
4/18/2019 7:34:18 AM Moleculin Biotech: US FDA OKs Fast Track Designation For Annamycin For Treatment Of Refractory Acute Myeloid Leukemia
4/11/2019 7:33:37 AM Moleculin Announces Agreement With Emory University To Conduct Phase 1 Clinical Trial Of WP1066 In Pediatric Brain Tumor
4/3/2019 7:31:54 AM Moleculin Announces Preclinical Pancreatic Cancer Data Presented At AACR Annual Meeting
3/27/2019 9:10:20 AM Moleculin Biotech Prices Underwritten Public Offering Of Aggregate Of 5.25 Mln Units At $1.00/unit
3/19/2019 7:33:03 AM Moleculin Biotech Says First Patients Enrolled In Lymphoma Clinical Trial
3/18/2019 4:06:36 PM Moleculin Announces Sloan Kettering Joins Its Science Advisory Board
2/7/2019 7:34:57 AM Moleculin Biotech Gets Approval To Begin Clinical Trials In Poland For Its STAT3 Inhibitor, WP1220
2/5/2019 7:34:52 AM Moleculin: FDA Grants Orphan Drug Designation For Its Brain Tumor Drug WP1066
1/3/2019 7:37:10 AM Moleculin Announces Positive Data For Its Pancreatic Cancer Drug Candidate WP1732
12/6/2018 7:32:39 AM Moleculin Announces FDA Filing For Orphan Drug Designation For Glioblastoma Drug
12/4/2018 7:35:52 AM Moleculin Biotech Announces Breakthrough Discovery For Its WP1066
11/28/2018 7:39:15 AM Moleculin Announces New Data Further Supporting Its Lead Drug WP1732 For Treating Pancreatic Cancer